New hope for weight loss: Low-Dose drug trial targets obesity without diabetes
NCT ID NCT07513168
First seen Apr 23, 2026 · Last updated Jun 16, 2026 · Updated 12 times
Summary
This study is testing whether a low dose of the drug semaglutide can help obese adults lose weight and improve heart health. About 60 Pakistani adults who are obese but do not have diabetes will receive weekly injections for 24 weeks, along with diet and exercise advice. The main goal is to see how much weight they lose and if their health markers like blood pressure and cholesterol improve.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asian Institute of Medical Sciences
RECRUITINGHyderābād, Sindh, 71000, Pakistan
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.